Assembly Biosciences (ASMB) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Mar. 24, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'VTUS	'	'
Entity Common Stock, Shares Outstanding	'	23,396,259	'
Entity Registrant Name	'VENTRUS BIOSCIENCES INC	'	'
Entity Central Index Key	'0001426800	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$46.90

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$27,061,268	$20,489,219
Other current assets	63,672	59,584
Total current assets	27,124,940	20,548,803
Computer equipment, net of accumulated depreciation of $39,266 and $33,050	7,102	6,841
Total assets	27,132,042	20,555,644
Current liabilities:	'	'
Accounts payable	2,614,619	1,847,245
Accrued expenses	23,435	898,213
Total liabilities	2,638,054	2,745,458
Stockholders' equity:	'	'
Preferred stock, $.001 par value; 5,000,000 shares authorized; Series A non-voting convertible preferred stock: 220,000 and 0 issued and outstanding at December 31, 2013 and December 31, 2012, respectively	220	0
Common stock, $.001 par value; 50,000,000 shares authorized; 20,733,895 and 12,934,350 issued and outstanding at December 31, 2013 and December 31, 2012, respectively	20,734	12,934
Additional paid-in capital	135,827,557	110,116,766
Common stock issuable, 125,000 shares at December 31, 2013	368,750	0
Deficit accumulated during the development stage	-111,723,273	-92,319,514
Total stockholders' equity	24,493,988	17,810,186
Total liabilities and stockholders' equity	$27,132,042	$20,555,644

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Computer equipment, depreciation	$39,266	$33,050
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	20,733,895	12,934,350
Common stock, shares outstanding	20,733,895	12,934,350
Common stock issuable Shares	125,000	'
Series A Non-Voting Convertible Preferred Stock [Member]	'	'
Preferred stock, issued	220,000	0
Preferred Stock, Shares Outstanding	220,000	0

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	12 Months Ended		99 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Operating expenses:	'	'	'
Research and development	$15,029,078	$19,514,163	$74,072,484
General and administrative	4,575,701	5,341,333	24,162,102
Loss from operations	-19,604,779	-24,855,496	-98,234,586
Other income (expense):	'	'	'
Interest income	201,020	65,066	362,139
Interest expense:	'	'	'
Beneficial conversion charge	0	0	-6,001,496
Amortization of debt discount and warrants	0	0	-2,865,758
Interest expense	0	0	-4,983,572
Total other income (expense)	201,020	65,066	-13,850,826
Net loss	($19,403,759)	($24,790,430)	($111,723,273)
Basic and diluted net loss per common share (In dollars per share)	($1)	($1.94)	'
Weighted average common shares outstanding - basic and diluted (In shares)	19,393,486	12,726,551	'

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended		99 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flows from operating activities:	'	'	'
Net loss	($19,403,759)	($24,790,430)	($111,723,273)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Stock-based compensation	1,676,789	2,831,651	10,448,711
Stock - based payments to consultants	36,158	339,442	4,366,417
Amortization of deferred financing costs and debt discount	0	0	3,466,010
Non-cash research and development	0	0	1,087,876
Expenses paid on behalf of the Company satisfied through the issuance of notes	0	0	227,910
Depreciation	6,216	4,618	41,839
Changes in operating assets and liabilities:	'	'	'
Prepaid research and development	0	0	0
Other current assets	-4,088	2,545	-63,672
Accounts payable and accrued expenses	-107,404	232,384	2,450,518
Net cash used in operating activities	-17,796,088	-21,379,790	-79,614,177
Cash flows from investing activities:	'	'	'
Purchase of office and computer equipment	-6,477	-3,241	-48,941
Net cash used in investing activities	-6,477	-3,241	-48,941
Cash flows from financing activities:	'	'	'
Net Proceeds from initial public offering and other offerings	24,374,614	4,166,494	93,714,274
Proceeds from private placement	0	0	1,146,024
Proceeds from exercise of warrants and options	0	730,322	1,019,054
Proceeds from notes payable to Paramount Credit Partners, LLC	0	0	1,573,000
Repayment of Paramount Credit Partners, LLC Note	0	0	-1,573,000
Proceeds from notes payable to related parties	0	0	5,041,953
Repayment of notes payable - related party	0	0	-1,500,000
Payment for deferred financing costs	0	0	-1,431,603
Proceeds from utilization of short-term note and line of credit	0	0	419,380
Repayment of debt facilities	0	0	-419,380
Proceeds from term note payable	0	0	800,000
Repayment of term note payable	0	0	-800,000
Proceeds from receipt of subscriptions	0	0	4,684
Net cash provided by financing activities	24,374,614	4,896,816	106,724,386
Net (decrease) increase in cash and cash equivalents	6,572,049	-16,486,215	27,061,268
Beginning of period	20,489,219	36,975,434	0
End of period	27,061,268	20,489,219	27,061,268
Supplemental schedule of non-cash financing activities:	'	'	'
Warrants issued to placement agent	0	0	341,334
Warrants issued to investors in connection with convertible notes	0	0	1,166,989
Notes and accrued interest converted to common stock	0	0	14,003,158
Supplemental disclosure - cash paid for interest	0	0	685,397
Senior Notes 2007 [Member]	'	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Interest payable	0	0	1,598,104
Cash flows from financing activities:	'	'	'
Proceeds from Senior convertible notes	0	0	5,305,000
Senior Notes 2010 [Member]	'	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Interest payable	0	0	354,269
Cash flows from financing activities:	'	'	'
Proceeds from Senior convertible notes	0	0	3,425,000
Supplemental schedule of non-cash financing activities:	'	'	'
Debt discount	0	0	1,468,254
Related Parties [Member]	'	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Stock/Warrants issued	0	0	1,255,978
Interest payable	0	0	266,279
Related Parties [Member] | Senior Notes 2010 [Member]	'	'	'
Supplemental schedule of non-cash financing activities:	'	'	'
Notes and accrued interest converted to common stock	0	0	3,995,667
Paramount Credit Partners, LLC [Member]	'	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Interest payable	0	0	187,536
Supplemental schedule of non-cash financing activities:	'	'	'
Debt discount	0	0	782,376
License Agreement [Member]	'	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Stock/Warrants issued	0	0	414,825
Note Conversion [Member]	'	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Stock/Warrants issued	0	0	6,001,496
Vendor [Member]	'	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Stock/Warrants issued	$0	$0	$5,000

Consolidated_Statements_Of_Cha

Consolidated Statements Of Changes In Stockholders’ Equity (Deficiency) (USD $)

Total

Issuance During Period 1st

Issuance During Period 2nd

Founders and Employees

Founders and Employees

Licensor

Paramount Credit Partners, LLC

Vendor

Senior Notes 2010

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Preferred Stock [Member]

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Common Stock Issuable [Member]

Deficit Accumulated During the Development Stage

Common And Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

Issuance During Period 1st

Issuance During Period 2nd

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Issuance During Period 1st

Issuance During Period 2nd

Founders and Employees

Founders and Employees

Licensor

Vendor

USD ($)

USD ($)

Issuance During Period 1st

Issuance During Period 2nd

Founders and Employees

Founders and Employees

Licensor

Paramount Credit Partners, LLC

Vendor

Senior Notes 2010

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Issuance During Period 1st

Issuance During Period 2nd

USD ($)

USD ($)

USD ($)

Issuance During Period 1st

Issuance During Period 2nd

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Beginning Balance at Oct. 07, 2005

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning Balance (in shares) at Oct. 07, 2005

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

368,012

9,677

18,401

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued

'

'

'

4,564

120

228

'

'

'

'

'

'

368

10

18

'

'

'

'

'

4,196

110

210

'

'

'

'

'

'

Stock-based compensation

16,655

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,655

'

'

'

'

'

'

'

'

'

'

'

Warrants issued

164,284

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

164,284

'

'

'

'

'

'

'

'

'

'

'

Net loss

-4,567,894

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-4,567,894

'

Ending Balance at Dec. 31, 2007

-4,382,043

'

'

'

'

'

'

'

'

396

'

'

'

'

'

'

'

185,455

'

'

'

'

'

'

'

'

'

-4,567,894

'

Beginning Balance (in shares) at Dec. 31, 2007

'

'

'

'

'

'

'

'

'

396,090

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued (in shares)

'

'

'

'

'

'

'

'

'

18,977

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued

929,457

'

'

'

'

'

'

'

'

19

'

'

'

'

'

'

'

929,438

'

'

'

'

'

'

'

'

'

'

'

Additional shares issued in January 2011 in connection with the December 22, 2010 conversion of notes into common stock

'

'

'

'

'

'

'

'

'

29,861

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of notes and accrued interest to common stock in December 2010 at $4.20 per share

1,803,234

'

'

'

'

'

'

'

'

30

'

'

'

'

'

'

'

1,803,204

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

460,822

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

460,822

'

'

'

'

'

'

'

'

'

'

'

Warrants issued

'

177,050

340,860

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

177,050

340,860

'

'

'

'

'

'

'

'

'

Net loss

-8,786,430

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-8,786,430

'

Ending Balance at Dec. 31, 2008

-9,457,050

'

'

'

'

'

'

'

'

445

'

'

'

'

'

'

'

3,896,829

'

'

'

'

'

'

'

'

'

-13,354,324

'

Ending Balance (in shares) at Dec. 31, 2008

'

'

'

'

'

'

'

'

'

444,928

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,016

403

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued

'

'

'

'

'

25,000

'

5,000

'

'

'

'

'

'

2

'

'

'

'

'

'

'

24,998

'

5,000

'

'

'

'

Stock-based compensation

123,758

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

123,758

'

'

'

'

'

'

'

'

'

'

'

Warrants issued

'

'

'

'

'

'

480,049

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

480,049

'

'

'

'

'

Net loss

-4,539,405

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-4,539,405

'

Ending Balance at Dec. 31, 2009

-13,362,648

'

'

'

'

'

'

'

'

447

'

'

'

'

'

'

'

4,530,634

'

'

'

'

'

'

'

'

'

-17,893,729

'

Beginning Balance (in shares) at Dec. 31, 2009

'

'

'

'

'

'

'

'

'

447,347

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

2,900,000

'

'

'

64,933

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued

'

15,184,344

'

'

'

389,596

'

'

'

'

2,900

'

'

'

65

'

'

'

15,181,444

'

'

'

389,531

'

'

'

'

'

'

Additional shares issued in January 2011 in connection with the December 22, 2010 conversion of notes into common stock

'

'

'

'

'

'

'

'

'

3,334,085

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of notes and accrued interest to common stock in December 2010 at $4.20 per share

14,003,158

'

'

'

'

'

'

'

'

3,334

'

'

'

'

'

'

'

13,999,824

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

2,194,535

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,194,535

'

'

'

'

'

'

'

'

'

'

'

Beneficial conversion charge recorded on notes and interest converted to common stock in December 2010

6,001,496

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,001,496

'

'

'

'

'

'

'

'

'

'

'

Warrants issued

'

'

'

'

'

161,552

'

'

2,344,708

'

'

'

'

'

'

'

'

'

'

'

'

'

161,552

'

'

2,344,708

'

'

'

Net loss

-15,290,625

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-15,290,625

'

Ending Balance at Dec. 31, 2010

11,626,116

'

'

'

'

'

'

'

'

6,746

'

'

'

'

'

'

'

44,803,724

'

'

'

'

'

'

'

'

'

-33,184,354

'

Ending Balance (in shares) at Dec. 31, 2010

'

'

'

'

'

'

'

'

'

6,746,365

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

435,000

5,175,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued

'

2,420,776

47,568,047

'

'

'

'

'

'

'

435

5,175

'

'

'

'

'

'

2,420,341

47,562,872

'

'

'

'

'

'

'

'

'

Warrants exercised (in shares)

'

'

'

'

'

'

'

'

'

50,034

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised

288,732

'

'

'

'

'

'

'

'

50

'

'

'

'

'

'

'

288,682

'

'

'

'

'

'

'

'

'

'

'

Additional shares issued in January 2011 in connection with the December 22, 2010 conversion of notes into common stock

'

'

'

'

'

'

'

'

'

7

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

2,982,949

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,982,949

'

'

'

'

'

'

'

'

'

'

'

Stock-based payments for options issued to consultants

3,990,817

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,990,817

'

'

'

'

'

'

'

'

'

'

'

Net loss

-34,344,730

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-34,344,730

'

Ending Balance at Dec. 31, 2011

34,532,707

'

'

'

'

'

'

'

'

12,406

'

'

'

'

'

'

'

102,049,385

'

'

'

'

'

'

'

'

'

-67,529,084

'

Ending Balance (in shares) at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

12,406,406

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

68,240

354,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued

'

427,817

4,166,494

'

'

'

'

'

'

'

68

355

'

'

'

'

'

'

427,749

4,166,139

'

'

'

'

'

'

'

'

'

Warrants exercised (in shares)

11,620

'

'

'

'

'

'

'

'

'

45,834

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised

'

302,505

'

'

'

'

'

'

'

'

46

'

'

'

'

'

'

'

302,459

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

'

'

'

2,831,651

339,442

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,831,651

339,442

'

'

'

'

'

'

'

Shares issued in cashless exercise (in shares)

'

'

'

'

'

'

'

'

'

'

11,620

47,550

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in cashless exercise

'

'

'

'

'

'

'

'

'

'

11

48

'

'

'

'

'

'

-11

-48

'

'

'

'

'

'

'

'

'

Net loss

-24,790,430

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-24,790,430

'

Ending Balance at Dec. 31, 2012

17,810,186

'

'

'

'

'

'

'

'

12,934

'

'

'

'

'

'

'

110,116,766

'

'

'

'

'

'

'

'

'

-92,319,514

'

Beginning Balance (in shares) at Dec. 31, 2012

'

'

'

'

'

'

'

'

'

12,934,350

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued (in shares)

'

'

'

'

'

'

'

'

'

2.46

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued

19,204,614

'

'

'

'

'

'

'

'

7,799,545

'

'

'

'

'

'

'

19,196,814

'

'

'

'

'

'

'

'

'

'

7,800

Preferred Stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

220,000

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock issued

5,170,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

220

5,169,780

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,308,039

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,308,039

'

'

'

'

'

'

'

'

'

'

'

Stock-based payments for options issued to consultants

36,158

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

0

36,158

'

'

'

'

'

'

'

'

0

0

0

Net loss

-19,403,759

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-19,403,759

'

Restricted stock granted to four employees April 2013 expense thru December 2013

368,750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

368,750

'

'

Ending Balance at Dec. 31, 2013

$24,493,988

'

'

'

'

'

'

'

'

$20,733,895

'

'

'

'

'

'

$220,000

$135,827,557

'

'

'

'

'

'

'

'

$368,750

($111,723,273)

$20,954

Consolidated_Statements_Of_Cha1

Consolidated Statements Of Changes In Stockholders’ Equity (Deficiency) (Parenthetical) (USD $)

12 Months Ended

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2008

Dec. 31, 2011

Dec. 31, 2007

Dec. 31, 2007

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2007

Dec. 31, 2009

Preferred Stock [Member]

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 1st

Issuance During Period 2nd

Issuance During Period 2nd

Founders and Employees

Founders and Employees

Licensor

Licensor

Licensor

Vendor

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Issuance During Period 1st

Issuance During Period 2nd

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Stock issued, per share

'

'

$25

'

$2.62

$12.45

$6

$6

'

$10

$0.01

$0.01

$6

$12.40

$0.01

$12.40

Conversion of notes and accrued interest to common stock, per share

$4.20

$4.20

'

$60.39

'

'

'

'

$60.39

'

'

'

'

'

'

'

Organization_Business_and_Basi

Organization, Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Organization, Business and Basis Of Presentation [Abstract]	'
Organization, Business and Basis of Presentation	'
	Note 1 - Organization, Business and Basis of Presentation:
	Organization and business:
	Ventrus BioSciences Inc. (“Ventrus” or the “Company”) is a development-stage specialty pharmaceutical company focused on the late-stage development and commercialization of gastrointestinal products. Ventrus, formerly known as South Island BioSciences, Inc., was incorporated in the State of Delaware on October 7, 2005 and commenced operations in April 2007.
	Basis of presentation:
	The accompanying audited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.
	The Company’s primary activities since incorporation have been organizational activities, including recruiting personnel, acquiring licenses for its pharmaceutical compound pipeline, performing business and financial planning, conducting clinical and nonclinical trials, performing research and development, and raising funds through the issuance of debt and common stock.
	The Company is in the development stage and has funded its operations primarily through the issuance of equity and debt. The Company expects to continue to expend substantial amounts for continued product research, development, and commercialization activities for the foreseeable future. Management believes the Company’s funds are sufficient to continue operations through the U.S. Food and Drug Administration (“FDA”) approval and initial launch and commercialization of diltiazem. Assuming such approval and launch, thereafter, continuation of the Company will be dependent on its ability to achieve profitable operations or obtain additional financing. There is no assurance, however, that such financing will be available or that the Company’s efforts ultimately will be successful.
	Capital resources:
	The Company has not derived any revenue from product sales to date as our products have not been approved for sale by the FDA or any foreign regulatory agency.  Since inception, the Company’s operations have been financed primarily through the sale of equity securities, the proceeds from the exercise of warrants and stock options and issuance of debt.  The Company has incurred losses from operations and negative cash flows since inception and expects to continue to incur substantial losses for the next several years as it continues its product development efforts. Management believes the Company currently has sufficient funds to meet its operating requirements for the next twelve months. If the Company cannot generate significant cash from its operations, it intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, or other arrangements and it cannot assure such funding will be available on reasonable terms, or at all.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 2 - Summary of Significant Accounting Policies:
	Cash and cash equivalents:
	All highly liquid investments with maturities of three months or less at the time of purchase are considered to be cash equivalents.  All of the Company’s cash equivalents have liquid markets and high credit ratings.  The Company maintains its cash in bank deposit and other accounts, the balances of which, at times and at December 31, 2013, exceed federally insured limits.
	Use of estimates:
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.
	Significant estimates inherent in the preparation of the accompanying financial statements include the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.
	Additionally, the Company provides a valuation allowance for deferred income tax assets when it is considered more likely than not that all or a portion of such deferred income tax assets will not be realized.
	Computer equipment:
	Computer equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the related assets of three years.
	Stock-based compensation:
	The Company’s share-based compensation cost is measured at grant date, using the Black-Scholes option pricing model to estimate the fair value of stock option and warrant awards, and is recognized as expense over the employee’s or director’s requisite service period on a straight-line basis.  The Company accounts for stock options and warrants granted to non-employees on a fair value basis which is estimated using the Black-Scholes option pricing model.  The initial non-cash charge to operations for non-employee options and warrants with vesting are revalued at the end of each reporting period until vested and recognized as consulting expense over the related vesting period. The Company valued the restricted stock grant, 75% of which vests in three equal installments when the 20-day trading volume weighted average price of the Company’s common stock is at least $4.15, $5.15 and $6.15, using the Monte Carlo simulation model.
	Warrants:
	For the purpose of valuing the warrants (See Notes 3 and 8), the Company used the Black-Scholes option pricing model utilizing the following assumptions.  To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of the Company’s awards.  The Company estimated the expected life of the warrants based on the full term of the warrant.   The expected dividend yield reflects the Company’s current and expected future policy for dividends on its common stock.  The expected stock price volatility for the Company’s stock was calculated by examining historical volatilities for publicly traded industry peers as the Company did not have any trading history for its common stock at the time the grants were issued.
	Warrants, or any other detachable instruments issued in connection with debt financing agreement not required to be recorded at fair value, are accounted for using the relative fair value method and allocated to additional paid-in capital and recorded as a reduction in the carrying value of the related debt.  This discount is amortized to interest expense from the issuance date through the maturity date of the debt using the effective interest method.
	Beneficial conversion feature:
	When the conversion feature of conventional convertible debt provides for a rate of conversion that is below market value, this feature is characterized as a beneficial conversion feature (“BCF”).  Prior to the determination of the BCF, the proceeds from the debt instrument are first allocated between the convertible debt and any detachable free standing instruments that are included, such as common stock warrants.  The Company has disclosed the contingent nature of its BCFs (See Notes 3 and 8) and has recorded their effects.
	Research and development:
	Research and development expenses include personnel and facility-related expenses, third party contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services. Research and development costs are expensed as incurred.  In instances where the Company enters into agreements with third parties for clinical trials, manufacturing and process development, research and other consulting activities, costs are expensed as services are performed. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments, and payments upon the completion of milestones or receipt of deliverables.
	The Company’s accruals for clinical trials are based on estimates of the services received and pursuant to contracts with the respective clinical trial centers and clinical research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical trial activities in the ongoing development of potential products.  The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows.  Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, and the completion of portions of the clinical trial or similar conditions.  The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received.  As such, expense accruals related to clinical trials are recognized based on the estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.
	Income taxes:
	The Company’s income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized.
	The Company has adopted the provisions that tax positions must meet a “more-likely-than-not” recognition threshold to be recognized. The Company has no unrecognized tax benefits recorded for the years ended December 31, 2013 and 2012. When an accrual for interest and penalties is required, interest and penalties will be recognized in tax expense. The Company files income tax returns in the U.S. federal jurisdiction and in New York. There are currently no federal income tax examinations in process. The 2010 through 2013 tax years remain subject to examination by the Internal Revenue Service and other taxing authorities for U.S. federal and state/local tax purposes. The Company does, however, have prior year net operating losses dating back to 2007, which are subject to examination.
	Loss per common share:
	Basic net loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period.  Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive.  Since the Company has only incurred losses, basic and diluted net loss per share is the same.  The number of potentially dilutive securities (options, warrants and unvested shares) excluded from the diluted loss per share calculation at December 31, 2013 and 2012 was 3,574,537 and 2,753,126, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure	'
	Note 3 - Related Party Transactions:
	The following are descriptions of the Company’s related party transactions that have been entered into, modified, terminated, or were still in effect in 2013.
	Paramount BioSciences, LLC and Affiliates:
	Paramount Corporate Development, LLC:
	From April 2007 through August 31, 2008, pursuant to a contractual arrangement with Paramount Corporate Development, LLC (“Paramount”), an affiliate of Dr. Lindsay A. Rosenwald, M.D., formerly a significant investor in and stockholder of the Company, the Company incurred $425,000 under this arrangement and as of December 31, 2013 and 2012, owed $100,000, which is included in accounts payable.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure	'
	Note 4 - Income Taxes:
	There was no current or deferred income tax provision for the years ended December 31, 2013 and 2012.
	The Company’s deferred tax assets as of December 31 consist of the following:
		2013			2012
	Net operating loss	$	32,193,000		$	23,792,000
	Stock-based compensation		6,617,000			5,808,000
	In-Process Research & Development		6,017,000			5,014,000
	Research and development credits		2,149,000			783,000
	Totals		46,976,000			35,397,000
	Less: valuation allowance		-46,976,000			-35,397,000
		$	-		$	-
	A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The net increase in the total valuation allowance for the years ended December 31, 2013 and 2012 was $11,579,000 and $9,132,000, respectively. The tax benefit assumed the Federal statutory tax rate of 34% and a state and local tax rate of 11% and has been fully offset by the aforementioned valuation allowance.
	At December 31, 2013, the Company had potentially utilizable gross Federal net operating loss carry-forwards of approximately $73,000,000, State net operating loss carry-forwards of approximately $67,000,000 and research and development credit carry forward of approximately $2,149,000, all of which expire between 2027 and 2031.
	An ownership change under Internal Revenue Code (“IRC”) Section 382 is likely to have occurred due to common stock issued in the IPO and debt conversions in December 2010. Due to the change in ownership provisions of the IRC, the availability of the Company’s net operating loss carry forwards may be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carry forwards. The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and therefore no determination has been made whether the net operating loss carry forward is subject to any IRC Section 382 limitation. To the extent there is a limitation, there would be a reduction in the deferred tax asset with an offsetting reduction in the valuation allowance.
		2013				2012
	Statutory Federal tax rate		-34	%			-34	%
	Statutory state and local income taxes (net of Federal)		-11	%			-7	%
	Effect of valuation allowance		45	%			41	%
	Effective tax rate		0	%			0	%

Commitments

Commitments	12 Months Ended
	Dec. 31, 2013
Other Commitments [Abstract]	'
Commitments	'
	Note 5 - Commitments:
	Employment agreements:
	The Company’s Chief Executive Officer had an employment agreement which provided for a base salary of $375,000 per year, a guaranteed bonus of $75,000 per year and an annual performance-based bonus of up to 50% of his base salary.  The agreement also provided incentive bonuses of $250,000 and $500,000 in the event that the Company’s market capitalization exceeded specified levels.  The first threshold was met and the $250,000 bonus was paid in the third quarter of 2011. The second threshold, which was to be paid in a combination of cash and shares of common stock, never occurred. The agreement expired on December 21, 2013, in accordance with its terms.
	The Chief Financial Officer had an employment agreement which provided for a base salary of $250,000 per year.  The agreement also provided incentive bonuses of $250,000 and $500,000 in the event that the Company’s market capitalization exceeded specified levels.  The first threshold was met and the $250,000 bonus was paid in the third quarter of 2011. The second threshold, which was to be paid in a combination of cash and shares of common stock, never occurred. The agreement expired on December 21, 2013, in accordance with its terms.
	On January 15, 2014, the Company entered into employment agreements, with the Chief Executive Officer and the Chief Financial Officer, which were effective as of December 22, 2013 (see Note 10).

Stockholders_Transactions

Stockholders' Transactions	12 Months Ended
	Dec. 31, 2013
Stockholders' Transactions [Abstract]	'
Stockholders' Transactions	'
	Note 6 - Stockholders’ Transactions:
	Common and Preferred Stock Transactions:
	During March and April 2007, the Company issued 368,012 shares of common stock to its founders for $4,564, or $0.0124 per share.
	During May and June 2007, the Company issued 9,677 shares of common stock to its employees for $120, or $0.0124 per share.  During August 2007, the Company issued 18,401 shares of common stock at $0.0124 per share in accordance with the license agreement between the Company and S.L.A. Pharma (see Note 7).  During 2007, the Company recorded $228 of stock-based research and development expense in connection with this license.
	During June through September 2008, the Company issued 18,977 shares of common stock and 3,796 warrants at $60.39 per unit (consisting of a share of common stock with 20% warrant coverage) in connection with a private placement financing at $60.39 per unit. Each warrant has a seven-year term and an exercise price of $66.46.  The Company raised $929,457 of net proceeds.
	During July 2008, the Company issued 29,861 shares of common stock and 6,151 warrants at $60.39 per unit (consisting of a share of common stock with 20% warrant coverage) to related parties in connection with the conversion of amounts outstanding under certain promissory notes. Each warrant has a seven-year term and an exercise price of $66.46. The warrants had a fair value of $340,860 and were expensed on issuance since the promissory notes were converted.
	The fair value of the warrants granted, mentioned in the preceding paragraph, was based on the following assumptions:
	Risk-free interest rate		3.89	%
	Expected volatility		128.18	%
	Expected life of warrants		5 years
	Expected dividend yield		0	%
	During December 2009, the Company issued 2,016 shares of common stock to S.L.A. Pharma pursuant to an amendment to the license agreement between the Company and S.L.A. Pharma, and 403 shares of common stock to a vendor, each at a value of $12.40 per share, recording an expense of $25,000 and $5,000 to research and development expense, respectively.
	In connection with the Company’s IPO, all of the issued and outstanding convertible notes issued in 2007 and 2010 converted into shares of common stock pursuant to the terms of those notes.  All principal and accrued interest on the 2007 and 2010 convertible notes converted at per share price of $4.20, which was 70% of the public offering price of $6.00 per share in the IPO, resulting in an aggregate of 1,642,802 shares of common stock issued upon conversion of the 2007 convertible notes and an aggregate of 1,421,834 shares of common stock issued upon conversion of the 2010 convertible notes.  Also in connection with the IPO, and pursuant to their terms, the promissory notes issued to Paramount BioSciences, Inc. and Capretti Grandi LLC, were converted at a per share price of $4.20, which was 70% of the public offering price of $6.00 per share in the IPO, resulting in an aggregate of 269,449 shares of common stock issued upon conversion of these notes.
	On December 22, 2010, the Company issued 2,900,000 shares of its common stock in an IPO at $6.00 per share and received net proceeds of $15,184,344, after deduction of underwriting discounts, commissions and other expenses related to the IPO.
	Pursuant to the terms of the license agreement between the Company and S.L.A Pharma, the Company was obligated to issue to S.L.A. Pharma that number of additional shares of common stock so that, when added to the 18,401 shares initially issued, the new and old shares had an estimated fair market value equal to $500,000 (based on the price per share paid in the financing). The closing of the Company’s IPO triggered this obligation.  As a result, the Company issued 64,933 shares of its common stock to S.L.A. Pharma on December 22, 2010.  The Company valued the stock issuance to S.L.A. Parma at $389,597 and expensed the full amount to research and development expense as of December 31, 2010.
	On January 7, 2011, the Company issued 435,000 shares of its common stock to fulfill the over-allotment option that it granted to the underwriters as part of the IPO and raised net proceeds of $2,420,776.
	During the twelve months ended December 31, 2011, the Company issued an aggregate of 50,034 shares of common stock pursuant to the exercise of warrants with an average exercise price of $5.77.
	On July 19, 2011, the Company issued 5,175,000 shares of its common stock in an underwritten public offering and raised net proceeds of $47,568,047.
	The Company filed a shelf registration statement with the Securities and Exchange Commission, which became effective on February 10, 2012, under which it may offer shares of its common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in units, in one or more offerings, up to a total dollar amount of $100,000,000. As part of the shelf registration statement, the Company included a prospectus for an at-the-market common equity sales program for the sale of up to $20,000,000 of common stock. In May and June 2012, the Company sold an aggregate of 354,700 shares under this program, resulting in net proceeds of approximately $4,166,000, or $11.75 per share. In February 2013, the Company sold an aggregate of 6,670,000 shares of common stock and 220,000 shares of Series A Non-Voting Preferred Stock, which are convertible into 2,200,000 shares of common stock, under the shelf registration statement, resulting in net proceeds of approximately $20,800,000. In September 2013, the Company amended its at-the-market sales agreement to cover the sale of up to $20,521,567 of common stock in addition to what had been sold previously. In September and October 2013, the Company sold an aggregate of 1,129,545 shares of common stock under the amended at-the-market common equity sales program, resulting in net proceeds of approximately $3,600,000, or $3.20 per share. As of December 31, 2013, an aggregate of approximately $75,000,000 worth of securities was available under the shelf registration statement out of which approximately $16,900,000 of common stock was available for the at-the-market common equity sales program.
	See Note 10 for transactions subsequent to December 31, 2013.
	Common Stock Options and Warrants:
	Stock Options:
	In 2007, the Company established a stock incentive plan (the “2007 Plan”) under which incentive stock and/or options could be granted to officers, directors, consultants and key employees of the Company for the purchase of up to 483,871 shares of the Company’s common stock. The options could have a maximum term of ten years, vest over a period to be determined by the Company’s Board of Directors and have an exercise price at or above fair market value on the date of grant.
	There were no options issued under the 2007 Plan in 2008 or 2009.
	On May 11, 2010, the Company granted options to purchase 2,016 shares of its common stock to a director under the 2007 Plan with an exercise price of $6.00.  The Company valued these options at $9,714 and expensed the full amount on the grant date since the options were fully vested.
	The Company terminated the 2007 Plan in July 2010, but the 2,016 options granted under the 2007 Plan remain outstanding.
	In August 2010, the Company’s stockholders approved the 2010 Equity Incentive Plan (the “2010 Plan”). In May 2011, the Company’s stockholders approved an amendment to the 2010 Plan to increase the shares reserved for issuance from 2,467,200 to 3,967,200 shares of the Company’s common stock. The 2010 Plan authorizes the Company to issue equity incentive awards in the form of shares, options or other awards based on Ventrus common stock as part of an overall compensation package to provide performance-based compensation to attract and retain qualified personnel.
	In November 2010, the Company granted options to non-employee directors to purchase an aggregate of 160,000 shares under the 2010 Plan. In addition, under Dr. Ellison’s and Mr. Barrett’s respective employment agreements, in connection with the closing of the Company’s IPO, the Company granted to Dr. Ellison and Mr. Barrett options under the 2010 plan to purchase shares of the Company’s common stock with an exercise price of $6.00, which was equal to the initial public offering price per share, in an amount equal to 7.5% (573,599 shares) and 4.0% (305,920 shares), respectively, of the Company’s fully diluted capitalization on that date.
	In 2011, the Company granted options to purchase 30,000 shares to three of its directors, options to purchase an aggregate of 552,440 shares to four employees and options to purchase an aggregate of 384,240 shares to seven consultants, all pursuant to the 2010 Plan with exercise prices at or greater than the then market value of the Company’s common stock ($6.00 - $15.77 per share).
	In 2012, the Company granted options to purchase 35,000 shares to a new director and 228,000 options to purchase shares to eight employees which included three new employees. Additionally, the company granted options to purchase an aggregate of 162,740 shares to seven consultants all pursuant to the 2010 Plan. The exercise prices of the options granted were at the then market value of the Company’s common stock ($3.60 - $10.62 per share).
	In 2013, the Company granted options to purchase 30,000 shares to three directors and 500,000 options to purchase shares to five new employees. The exercise prices of the options granted were at the then market value of the Company’s common stock ($2.47 - $3.31 per share).
	A summary of the Company’s option activity under its option plans and related information is as follows:
		Year Ended									Year Ended
		December 31, 2013									December 31, 2012
		Shares				Weighted			Aggregate		Shares			Weighted		Aggregate
						Average			Intrinsic					Average		Intrinsic
						Exercise			Value					Exercise		Value
						Price								Price
	Outstanding at beginning of period			1,878,475		$	6.72		$	-			2,046,455	$	6.4	$	-
	Granted			530,000		$	2.88		$	-			425,740	$	7.64	$	-
	Exercised			-		$	-			-			-168,240		6.11		-
	Forfeited			-69,984		$	7.6		$	-			-425,480		6.64		-
	Outstanding at end of year			2,338,491		$	5.87		$				1,878,475	$	6.72	$	-
	Options exercisable at end of period			2,322,518		$	6.31		$	-			1,618,820	$	6.51	$	-
	Vested or expected to vest at December 31			2,338,491			-			-			1,878,475		-		-
	Shares available on December 31 for options that may be granted			1,390,485			-			-			1,920,485		-		-
	Included in the options exercised in 2012 were 100,000 options exercised in a cashless exercise for 47,550 shares of common stock.
	The Company expects that all outstanding unvested options will vest. The fair value of the options granted for the year ended December 31, 2013 and 2012, was based on the following assumptions:
			2013				2012
	Risk-free interest rate			1.23%-2.34	%			1.11%-1.32%
	Expected volatility			59.32%-77.34	%			76.31%-78.23%
	Expected life of options			7 years				7 years
	Expected dividend yield			0	%			0%
	Estimated future stock-based compensation expense relating to unvested stock options (for consultants based on the fair value at December 31, 2013) is as follows:
	Years Ending December 31,		Future Stock Option
			Compensation
			Expense
	2014			682,701
	2015			275,820
	2016			196,419
	2017			20,239
	Total estimated future stock-based compensation expense - stock options		$	1,175,179
	The weighted average remaining contractual life of options outstanding at December 31, 2013 is approximately 7.25 years.
Stock-based compensation expensed to research and development expense for the years ended December 31, 2013 and 2012 was $695,636 and $846,508, respectively.  Stock-based compensation expensed to general and administrative expense for the years ended December 31, 2013 and 2012 was $1,017,311 and $2,324,585, respectively.
Warrants:
During 2007, the Company granted 12,903 warrants to various consultants with an exercise price of $7.69 per share. Each warrant granted during 2007 vests equally over a three-year period and has a seven-year term.  During 2008, 1,613 of these warrants were forfeited due to the consultant’s relationship with the Company ending prior to the vesting period. All of the warrants that remain outstanding were fully vested at December 31, 2010.
On August 30, 2010, the Company issued a warrant to purchase 13,605 shares of its common stock with an exercise price of $1.24 per share to S.L.A. Pharma (see Note 7) pursuant to an amendment to the license agreement between the Company and S.L.A. Pharma.  The warrant was fully vested at issuance and the Company recognized the full amount of $161,552 of stock-based research and development expense as of December 31, 2010.
In connection with the Company’s financings in 2007, 2008, 2009 and 2010, the Company issued warrants to investors and/or placement agents to purchase shares of common stock as well as certain consulting warrants (See Note 8).
A summary of the Company’s warrant activity and related information is as follows:
		Year Ended					Year Ended
		31-Dec-13					December 31, 2012
		Shares		Weighted			Shares				Weighted
				Average							Average
				Exercise Price							Exercise Price
Outstanding at beginning of period		874,651		$	7.67				956,443		$	7.61
Granted		-		$	-				-		$	-
Exercised		-		$	-				81,792		$	7
Expired		13,605		$	1.24				-			-
Outstanding at end of year		861,046		$	7.77				874,651		$	7.67
Warrants exercisable at end of period		861,046		$	7.77				874,651		$	7.67
Included in the warrants exercised are 35,958 warrants exercised in a cashless exercise for 11,620 shares during the year ended December 2012. All outstanding warrants have vested and no additional expense is expected to be recorded in the future years.
Common Stock Grant:
On April 5, 2013, the Company granted restricted stock units to four employees under the 2010 Plan for an aggregate of 500,000 shares of common stock.  Of these units, 25% vested immediately at the grant date.  The remaining 75% of the units will vest in equal 25% tranches if the 20 trading day volume-weighted average price of our common stock as reported on the NASDAQ Capital Market is at least $4.15, $5.15 and $6.15, respectively .  The performance period for the unvested restricted stock units ends on June 30, 2016; if one or more of the stock price thresholds are not met by that date the unvested units will expire.  Each employee elected to defer receipt of all shares issuable under the units, including the immediately vested shares, until the earliest of termination of employment, a change in control of Ventrus, or April 1, 2015. The restricted stock units were issued to employees and officers at a price equal to the market price of the Company’s stock at the date of grant.   The Company estimated the fair value of the restricted stock units using the Monte Carlo valuation model with the following assumptions; volatility of 56.10% , risk free interest rate of 1.934%, and dividend rate of 0%.  The total estimated fair value of the restricted stock units is approximately $1,135,000.  Compensation costs for restricted stock award are being recognized on a straight-line basis over the performance period.  The first 25% of restricted stock was immediately expensed.
A summary of the status of our restricted stock units as of December 31, 2013 is as follows:
	Year Ended December 31, 2013
					Weighted Average
	Shares				Grant Date Fair Value
					Per Share
Restricted stock units as of January 1, 2013			0		$	-
Granted April 5, 2013			500,000		$	2.27
Shares vested and issuable			-125,000		$	2.95
Restricted stock units as of December 31, 2013			375,000		$	2.04

License_Agreements

License Agreements	12 Months Ended
	Dec. 31, 2013
License Arrangement [Abstract]	'
License Agreements	'
	Note 7 - License Agreements:
	S.L.A. Pharma, AG
	In March 2007, pursuant to an Exclusive License Agreement, S.L.A. Pharma, AG (“S.L.A. Pharma”) granted PBS a royalty-bearing license to sell, make and use diltiazem for treatment, through topical administration, of anal fissures and phenylepherine for treatment, through topical administration, of fecal incontinence in the United States, Canada and Mexico. Pursuant to the Exclusive License Agreement, PBS was obligated to form a company to develop the technologies referenced in the Exclusive License Agreement and issue a number of shares equal to 5% of such company’s outstanding common stock as of the effective date of the Exclusive License Agreement.  On August 2, 2007, the Company issued 18,401 shares to S.L.A. Pharma to satisfy this obligation.  In addition, the Company was obligated to issue to S.L.A. Pharma that number of additional shares of common stock so that the number of shares following specific transactions would have a fair market value equal to $500,000.  On December 22, 2010, the Company issued S.L.A Pharma an additional 64,933 shares to satisfy this obligation.
	In August 2007, pursuant to an Assignment and Assumption Agreement, PBS sold all of its rights in and arising out of the Exclusive License Agreement with S.L.A. Pharma to Ventrus for $1,087,876.  The corresponding U.S. and foreign patents and applications for the two compounds have been licensed to Ventrus under the Assignment and Assumption Agreement (the technology referred to collectively as the “Compound Technology”).  As consideration in part for the rights to the Compound Technology, an initial licensing fee of $250,000 was paid to S.L.A. Pharma and $50,000 for reimbursement of clinical development costs incurred by S.L.A. Pharma (these amounts were paid by PBS and were included in the consideration paid by the Company to PBS in connection with the Assignment and Assumption Agreement).  In the event that the Compound Technology is commercialized, the Company is obligated to pay to S.L.A. Pharma annual royalties, based upon net sales of the product. In addition, the Company is required to make payments to S.L.A. Pharma up to an aggregate amount of $20 million upon the achievement of various milestones related to regulatory events.  Should the Company make any improvements regarding the Compound Technology, the Company is required to grant S.L.A. Pharma licenses to use such improvements.
	As compensation for S.L.A. Pharma’s participation in the management and the development of the technologies, Ventrus is required to make separate payments to S.L.A. Pharma equal to $41,500 per month (“Monthly Payments”) for each of diltiazem and phenylephrine.  Per the agreement, Ventrus’ obligation to make these monthly payments until S.L.A. Pharma is no longer managing the development program for diltiazem. Pursuant to amendments to the Exclusive License Agreement, the Company, as of September 30, 2010, was no longer required to make additional payments for phenylephrine.  At December 31, 2013, the Company had no amounts due to S.L.A. Pharma.
	The Company is also required to reimburse S.L.A. Pharma for clinical development costs associated with the technology development of the diltiazem project. The Company’s total payment obligation for the diltiazem project is limited to $4,200,000.  The Company made $4,200,000 of payments to S.L.A. Pharma from August 2007 through December 31, 2011.
	On June 6, 2011, Ventrus further amended the Exclusive License Agreement with S.L.A. Pharma.  The amendment eliminates its potential $800,000 milestone payment to S.L.A. Pharma for the development of diltiazem, previously payable upon the completion of enrollment into the Phase III clinical trial that S.L.A. Pharma is conducting in Europe.  It also eliminates S.L.A. Pharma’s ability to terminate the license agreement at any time, with one month’s notice, in the event that Ventrus had failed to make a required payment and a third party wished to enter into a license agreement for diltiazem and phenylephrine, provided the termination would not have been effective if within that one-month period Ventrus paid all the then required payments under the agreement. Pursuant to the amendment, Ventrus must pay S.L.A. Pharma up to $1,000,000 in milestone payments, payable in four equal installments of $250,000 once specified thresholds of randomized patients are achieved in the Phase III trial for diltiazem that S.L.A. Pharma is conducting in Europe. The first two milestones were met and paid in the third quarter of 2011 and the third and fourth milestone was met and paid in the fourth quarter of 2011. Additionally, upon Ventrus’ receipt of a quality controlled final study report of the Phase III trial for diltiazem in Europe, Ventrus must pay S.L.A. Pharma $400,000 in development costs for diltiazem.  This report was received and the payment was made in February 2013.
	The Company is also required to reimburse S.L.A. Pharma for clinical development costs associated with the technology development of the phenylephrine project. S.L.A. Pharma has been paid $600,000 of services for the phenylephrine project through December 31, 2011.  S.L.A. Pharma did not provide Ventrus with any services for the phenylephrine project in 2011 or 2012 and management does not expect any services from SLA Pharma for the phenylephrine project in the foreseeable future.
	Sam Amer and Company, Inc.
	In March 2008, Ventrus entered into an exclusive worldwide license agreement with Sam Amer & Co., Inc., a California company (“Amer”), whereby Ventrus acquired certain patent rights to iferanserin for the topical treatment of any anorectal disorders. Through November 14, 2011, the Company made all contractual payments relating to the license agreement.  The license agreement terminated in November 2011 upon our acquisition of all rights, title and interest to iferanserin from Amer, discussed below.
	On June 5, 2011, the Company entered into an agreement with Amer to acquire all rights, title and interest to iferanserin and on November 14, 2011, closed on this transaction.  The Company paid an aggregate of $12.5 million to Amer in the transaction. Because the assets purchased (1) do not meet the definition of a business combination and (2) do not have alternative future use since the assets acquired are contingent on further development and clinical risk, we determined that the entire purchase price of the asset be expensed immediately as in-process research and development.
	On June 25, 2012, the Company reported that a Phase III, randomized, double-blind, placebo-controlled clinical trial of VEN 309 for the treatment of symptomatic hemorrhoids did not meet its endpoints. Based on the results of that Phase III trial, the Company ceased all activity related to VEN 309 and ended the program.
	Therabiome, LLC
	On November 8, 2013, the Company entered into an exclusive worldwide License and Collaboration Agreement with Therabiome, LLC (“Therabiome”), for all intellectual property and know-how owned or controlled by Therabiome relating to the oral delivery  of pharmaceutical drugs to specific sites in the intestine, using a pH sensitive controlled release platform technology. The Company is solely responsible for all research and development activities with respect to any product it develops under the license. For the license, the Company paid Therabiome an upfront non-refundable license fee of $300,000, which was expensed as research and development. The Company must pay Therabiome clinical and regulatory milestones for each product or therapy advanced from the platform, for U.S. regulatory milestones, depending on whether the milestone occurs before the filing of the first new drug application (“NDA”) for a product or after the first, second or third NDA filings. The Company also must pay Therabiome lesser amounts for foreign regulatory milestones, which vary by country and region, and depend on whether the milestone occurs before the filing of the first NDA filing for a product or after the first, second or third NDA filings, and which will be: one-third of the U.S. milestones paid upon a foreign equivalent of an investigational new drug application, or IND, and marketing approval for each product in the European Union or Japan; 10% of the U.S. milestones paid upon a foreign equivalent of  an IND and marketing approval for each product in China; 10% of the U.S. milestone paid upon marketing approval for each product in India and Brazil; and 1% of the U.S. milestone paid upon marketing approval for each product in all other countries. The Company also must pay Therabiome royalties on annual net sales of a product in the low to mid-single digit percentages plus, once annual net sales exceed two certain thresholds, a one-time cash payment upon reaching each threshold.

Private_Placements

Private Placements	12 Months Ended
	Dec. 31, 2013
Fair Value Of Placement Warrants [Abstract]	'
Private Placement Disclosure	'
	Note 8 - Private Placements:
	2007 Senior convertible notes:
	During 2007 and 2008, the Company issued 8% senior convertible notes in connection with a private placement in the aggregate principal amount of $5,305,000 (the “Bridge Notes”). The Bridge Notes were originally scheduled to mature on December 20, 2008, but the Company exercised its option to extend the maturity date to December 20, 2009, at an increased interest rate of 10%. The Company subsequently obtained the consent of the note holders to an additional extension of the maturity date of the Bridge Notes to September 10, 2010 and again to December 31, 2010. The completion of the Company’s IPO triggered the automatic conversion of the Bridge Notes and accrued interest into common stock at 70% conversion price of the IPO price. The Company valued the beneficial conversion feature of the 2007 Notes at $2,957,187, which was recorded as interest expense in 2010. The Company computed the conversion feature to be $2,957,187 by dividing the amount of debt and interest ($6,899,770), which is convertible into common stock by the conversion rate (70%). From this amount ($9,856,957) the amount of debt and interest ($6,899,770) was subtracted to determine the amount by which the instrument if-converted exceeds the conversion amount ($2,957,187).
	In connection with the offering of the Bridge Notes, Paramount Biocapital, Inc. (“PCI”) and the Company entered into a placement agency agreement dated October 9, 2007, pursuant to which the Company paid PCI and third party agents cash commissions of $243,600 and $19,250, respectively, for its services. The Company agreed to additional services by PCI during the 18-month period subsequent to March 11, 2008 which expired without any further amounts being paid. PCI is a related party to the Company since it is wholly-owned by Dr. Rosenwald.
	In addition, PCI and third party agents received seven-year warrants (the “Placement Warrants”). The amount of shares and the exercise price were to be determined based on whether a qualified financing occurred on or before December 21, 2009. The qualified financing did not occur by such date and as a result the number of shares subject to the Placement Warrants is 42,782 shares, an amount equal to 10% of the principal amount of the Bridge Notes purchased, divided by $12.40, with an exercise price equal to $12.40. PCI subsequently transferred the Placement Warrants among its employees. The Company estimated the value of the Placement Warrants using the Black-Scholes option pricing model at approximately $341,000 and recorded them as deferred financing costs, which were amortized to interest expense over the term of the Bridge Notes. The fair value of the Placement Warrants granted was based on the following assumptions:
	Risk-free interest rate	3.01% - 3.84	%
	Expected volatility	63.69% - 123.73	%
	Expected life of warrants	7 years
	Expected dividend yield	0	%
	2010 Senior Convertible Notes:
	In February, March, April and May 2010, the Company issued 8% senior convertible notes in connection with a private placement in the aggregate principal amount of $3,425,000 (the “2010 Notes”). The 2010 Notes matured on September 10, 2010. Upon the closing of a Qualified Financing (as defined below), the 2010 Notes plus any accrued but unpaid interest thereon were to convert into shares of the Company’s common stock at 70% of the price at which shares of common stock are sold in the Qualified Financing (the “IPO Price”). The completion of the Company’s IPO triggered the automatic conversion of the 2010 Notes. Upon conversion, the 2010 Notes were automatically cancelled.
	The Company valued the beneficial conversion feature of the 2010 Notes at $1,619,687, which was recorded as interest expense after the Qualified Financing was completed. The Company computed the conversion feature to be $1,619,687 by dividing the amount of debt and interest ($3,779,269), which is convertible into common stock by the conversion rate (70%). From this amount ($5,398,956) the amount of debt and interest ($3,779,269) was subtracted to determine the amount by which the instrument if-converted exceeds the conversion amount ($1,619,687).
	Each 2010 Noteholder holds a warrant to purchase that number of shares of the Company’s common stock equal to 50% of the principal amount of the 2010 Notes purchased by it divided by the IPO Price at a per share exercise price equal to 110% of the IPO Price, subject to adjustment. Each of these warrants will expire and no longer be exercisable after February 26, 2015. In connection with the Company’s IPO, the number of shares of common stock issuable pursuant to these warrants is an aggregate of 285,417 shares with an exercise price of $6.60 per share. The Company valued these warrants at $1,429,590 using the Black-Scholes option pricing model and has expensed such amount as of December 31, 2010. The fair value of the warrants granted was based on the following assumptions:
	Risk-free interest rate	2.02	%
	Expected volatility	124	%
	Expected life of warrants	5 years
	Expected dividend yield	0	%
	On February 26, 2010, a 2010 Note in the aggregate principal amount of $2,192,433 and related warrant were issued to PBS for the cancellation of certain debt, which is not included in the $3,425,000 of aggregate principal amount of 2010 Notes issued in the private placement. Including such converted debt, the total aggregate principal amount of 2010 Notes was $5,617,433. In connection with the Company’s IPO, these 2010 Notes converted into an aggregate of 1,421,834 shares of common stock. Upon conversion, these 2010 Notes were automatically cancelled.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Note 9 - Commitments and Contingencies:
	Litigation:
	In June 2012, the Company announced that is product iferanserin (VEN 309), failed to meet its end point at the completion of its Phase III clinical trial.  In May 2013 two purported class action lawsuits alleging violations of the federal securities laws were filed in New York against the Company, two of its executive officers and the lead underwriter of its initial public offering.  The lawsuits include allegations that, during the class period between December 17, 2010 and June 25, 2012, the Company and its executive officers and underwriter made various statements related to the Company’s product, iferanserin (VEN 309), including but not limited to, the market for the product, the potential competitors, and the results of clinical trials, thereby inflating the price of our common stock. The complaints seek unspecified damages, interest, attorneys’ fees, and other costs.  On July 23, 2013, the Court consolidated the actions and appointed lead plaintiffs and lead counsel.  On September 16, 2013, lead plaintiffs filed a consolidated amended complaint.  On September 16, 2013, lead plaintiffs filed a consolidated amended complaint.  On November 22, 2013, the Company filed a motion to dismiss the consolidated amended complaint (the “Motion to Dismiss”). The Motion to Dismiss has been fully briefed and the Court has taken the Motion to Dismiss under submission. Due to the early stage of these proceedings, the Company is unable to predict the outcome or reasonably estimate a range of possible loss relating to these claims.

Subsequent_Event

Subsequent Event	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 10- Subsequent Event
	On January 15, 2014, the Company entered into an employment agreement with its Chief Executive Officer and its Chief Financial Officer, with an effective date of December 22, 2013. Each agreement has a term of two years and will be automatically extended for additional one-year periods unless the Company notifies the officer at least 180 days prior to the then current expiration date that it intends to not extend the employment agreement. The employment agreements provide for a base salary of $475,000 per year for the Chief Executive Officer and $300,000 for the Chief Financial Officer, and an annual discretionary bonus of up to 50% of the officer’s base salary based on financial, clinical development and business milestones established by the Board of Directors.
	In January 2014, the Company sold an aggregate of 462,364 shares of its common stock in its at-the-market common equity offering program, resulting in net proceeds of approximately $1,763,000 or $3.81 per share.
	In February 2014, all 220,000 outstanding shares of the Company’s Series A non-voting convertible preferred stock converted into an aggregate of 2,200,000 shares of common stock.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Cash and Cash Equivalents	'
	Cash and cash equivalents:
	All highly liquid investments with maturities of three months or less at the time of purchase are considered to be cash equivalents.  All of the Company’s cash equivalents have liquid markets and high credit ratings.  The Company maintains its cash in bank deposit and other accounts, the balances of which, at times and at December 31, 2013, exceed federally insured limits.
Use of estimates	'
	Use of estimates:
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.
	Significant estimates inherent in the preparation of the accompanying financial statements include the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.
	Additionally, the Company provides a valuation allowance for deferred income tax assets when it is considered more likely than not that all or a portion of such deferred income tax assets will not be realized.
Computer Equipment	'
	Computer equipment:
	Computer equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the related assets of three years.
Stock-based compensation	'
	Stock-based compensation:
	The Company’s share-based compensation cost is measured at grant date, using the Black-Scholes option pricing model to estimate the fair value of stock option and warrant awards, and is recognized as expense over the employee’s or director’s requisite service period on a straight-line basis.  The Company accounts for stock options and warrants granted to non-employees on a fair value basis which is estimated using the Black-Scholes option pricing model.  The initial non-cash charge to operations for non-employee options and warrants with vesting are revalued at the end of each reporting period until vested and recognized as consulting expense over the related vesting period. The Company valued the restricted stock grant, 75% of which vests in three equal installments when the 20-day trading volume weighted average price of the Company’s common stock is at least $4.15, $5.15 and $6.15, using the Monte Carlo simulation model.
Warrants	'
	Warrants:
	For the purpose of valuing the warrants (See Notes 3 and 8), the Company used the Black-Scholes option pricing model utilizing the following assumptions.  To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of the Company’s awards.  The Company estimated the expected life of the warrants based on the full term of the warrant.   The expected dividend yield reflects the Company’s current and expected future policy for dividends on its common stock.  The expected stock price volatility for the Company’s stock was calculated by examining historical volatilities for publicly traded industry peers as the Company did not have any trading history for its common stock at the time the grants were issued.
	Warrants, or any other detachable instruments issued in connection with debt financing agreement not required to be recorded at fair value, are accounted for using the relative fair value method and allocated to additional paid-in capital and recorded as a reduction in the carrying value of the related debt.  This discount is amortized to interest expense from the issuance date through the maturity date of the debt using the effective interest method.
Beneficial Conversion Feature	'
	Beneficial conversion feature:
	When the conversion feature of conventional convertible debt provides for a rate of conversion that is below market value, this feature is characterized as a beneficial conversion feature (“BCF”).  Prior to the determination of the BCF, the proceeds from the debt instrument are first allocated between the convertible debt and any detachable free standing instruments that are included, such as common stock warrants.  The Company has disclosed the contingent nature of its BCFs (See Notes 3 and 8) and has recorded their effects.
Research and development	'
	Research and development:
	Research and development expenses include personnel and facility-related expenses, third party contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services. Research and development costs are expensed as incurred.  In instances where the Company enters into agreements with third parties for clinical trials, manufacturing and process development, research and other consulting activities, costs are expensed as services are performed. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments, and payments upon the completion of milestones or receipt of deliverables.
	The Company’s accruals for clinical trials are based on estimates of the services received and pursuant to contracts with the respective clinical trial centers and clinical research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical trial activities in the ongoing development of potential products.  The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows.  Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, and the completion of portions of the clinical trial or similar conditions.  The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received.  As such, expense accruals related to clinical trials are recognized based on the estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract.
Income taxes	'
	Income taxes:
	The Company’s income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized.
	The Company has adopted the provisions that tax positions must meet a “more-likely-than-not” recognition threshold to be recognized. The Company has no unrecognized tax benefits recorded for the years ended December 31, 2013 and 2012. When an accrual for interest and penalties is required, interest and penalties will be recognized in tax expense. The Company files income tax returns in the U.S. federal jurisdiction and in New York. There are currently no federal income tax examinations in process. The 2010 through 2013 tax years remain subject to examination by the Internal Revenue Service and other taxing authorities for U.S. federal and state/local tax purposes. The Company does, however, have prior year net operating losses dating back to 2007, which are subject to examination.
Loss per common share	'
	Loss per common share:
	Basic net loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period.  Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive.  Since the Company has only incurred losses, basic and diluted net loss per share is the same.  The number of potentially dilutive securities (options, warrants and unvested shares) excluded from the diluted loss per share calculation at December 31, 2013 and 2012 was 3,574,537 and 2,753,126, respectively.

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities	'
	The Company’s deferred tax assets as of December 31 consist of the following:
		2013			2012
	Net operating loss	$	32,193,000		$	23,792,000
	Stock-based compensation		6,617,000			5,808,000
	In-Process Research & Development		6,017,000			5,014,000
	Research and development credits		2,149,000			783,000
	Totals		46,976,000			35,397,000
	Less: valuation allowance		-46,976,000			-35,397,000
		$	-		$	-
Federal Income Tax Note	'
	To the extent there is a limitation, there would be a reduction in the deferred tax asset with an offsetting reduction in the valuation allowance.
		2013				2012
	Statutory Federal tax rate		-34	%			-34	%
	Statutory state and local income taxes (net of Federal)		-11	%			-7	%
	Effect of valuation allowance		45	%			41	%
	Effective tax rate		0	%			0	%

Stockholders_Transactions_Tabl

Stockholders' Transactions (Tables)	12 Months Ended
	Dec. 31, 2013
Assumptions for Weighted Average Fair Value of Options Granted	'
	The Company expects that all outstanding unvested options will vest. The fair value of the options granted for the year ended December 31, 2013 and 2012, was based on the following assumptions:
			2013				2012
	Risk-free interest rate			1.23%-2.34	%			1.11%-1.32%
	Expected volatility			59.32%-77.34	%			76.31%-78.23%
	Expected life of options			7 years				7 years
	Expected dividend yield			0	%			0%
Estimated Future Stock Based Expenses Relating to Unvested Stock Options	'
	Estimated future stock-based compensation expense relating to unvested stock options (for consultants based on the fair value at December 31, 2013) is as follows:
	Years Ending December 31,		Future Stock Option
			Compensation
			Expense
	2014			682,701
	2015			275,820
	2016			196,419
	2017			20,239
	Total estimated future stock-based compensation expense - stock options		$	1,175,179
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	'
	A summary of the status of our restricted stock units as of December 31, 2013 is as follows:
		Year Ended December 31, 2013
						Weighted Average
		Shares				Grant Date Fair Value
						Per Share
	Restricted stock units as of January 1, 2013			0		$	-
	Granted April 5, 2013			500,000		$	2.27
	Shares vested and issuable			-125,000		$	2.95
	Restricted stock units as of December 31, 2013			375,000		$	2.04
Stock Option [Member]	'
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award	'
	A summary of the Company’s option activity under its option plans and related information is as follows:
		Year Ended									Year Ended
		December 31, 2013									December 31, 2012
		Shares				Weighted			Aggregate		Shares			Weighted		Aggregate
						Average			Intrinsic					Average		Intrinsic
						Exercise			Value					Exercise		Value
						Price								Price
	Outstanding at beginning of period			1,878,475		$	6.72		$	-			2,046,455	$	6.4	$	-
	Granted			530,000		$	2.88		$	-			425,740	$	7.64	$	-
	Exercised			-		$	-			-			-168,240		6.11		-
	Forfeited			-69,984		$	7.6		$	-			-425,480		6.64		-
	Outstanding at end of year			2,338,491		$	5.87		$				1,878,475	$	6.72	$	-
	Options exercisable at end of period			2,322,518		$	6.31		$	-			1,618,820	$	6.51	$	-
	Vested or expected to vest at December 31			2,338,491			-			-			1,878,475		-		-
	Shares available on December 31 for options that may be granted			1,390,485			-			-			1,920,485		-		-
Warrant [Member]	'
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award	'
	A summary of the Company’s warrant activity and related information is as follows:
			Year Ended					Year Ended
			31-Dec-13					December 31, 2012
			Shares		Weighted			Shares				Weighted
					Average							Average
					Exercise Price							Exercise Price
	Outstanding at beginning of period		874,651		$	7.67				956,443		$	7.61
	Granted		-		$	-				-		$	-
	Exercised		-		$	-				81,792		$	7
	Expired		13,605		$	1.24				-			-
	Outstanding at end of year		861,046		$	7.77				874,651		$	7.67
	Warrants exercisable at end of period		861,046		$	7.77				874,651		$	7.67
Related Party Note Conversion [Member]	'
Schedule Of Fair Value Warrants Granted Assumptions	'
	The fair value of the warrants granted, mentioned in the preceding paragraph, was based on the following assumptions:
	Risk-free interest rate		3.89	%
	Expected volatility		128.18	%
	Expected life of warrants		5 years
	Expected dividend yield		0	%

Private_Placements_Tables

Private Placements (Tables)	12 Months Ended
	Dec. 31, 2013
Senior Convertible Notes 2007 [Member]	'
Schedule Of Fair Value Warrants Granted Assumptions	'
	Warrants granted was based on the following assumptions:
	Risk-free interest rate	3.01% - 3.84	%
	Expected volatility	63.69% - 123.73	%
	Expected life of warrants	7 years
	Expected dividend yield	0	%
Senior Convertible Notes 2010 [Member]	'
Schedule Of Fair Value Warrants Granted Assumptions	'
	The fair value of the warrants granted was based on the following assumptions:
	Risk-free interest rate	2.02	%
	Expected volatility	124	%
	Expected life of warrants	5 years
	Expected dividend yield	0	%

Organization_Business_and_Basi1

Organization, Business and Basis of Presentation - Additional Information (Details)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]	'
Entity Incorporation Date Of Incorporation	7-Oct-05
Entity Incorporation State Country Name	'Delaware

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Significant Accounting Policies [Line Items]	'	'
Potentially dilutive securities excluded from diluted loss per share calculation	3,574,537	2,753,126
Percentage Of Restricted Stock Units Vested Descriptions	'The Company valued the restricted stock grant, 75% of which vests in three equal installments when the 20-day trading volume weighted average price of the Companys common stock is at least $4.15, $5.15 and $6.15, using the Monte Carlo simulation model.	'
Computer Equipment [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Property, Plant and Equipment, Estimated Useful Lives	'three years	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Details) (Paramount [Member], USD $)	17 Months Ended
	Aug. 31, 2008	Dec. 31, 2013	Dec. 31, 2012
Paramount [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Monthly Consulting Services Fee	$425,000	'	'
Consulting Services Fee Payable	'	$100,000	$100,000

Income_Taxes_Deferred_Tax_Asse

Income Taxes - Deferred Tax Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred Tax Assets [Line Items]	'	'
Net operating loss	$32,193,000	$23,792,000
Stock-based compensation	6,617,000	5,808,000
In-Process Research & Development	6,017,000	5,014,000
Research and development credits	2,149,000	783,000
Totals	46,976,000	35,397,000
Less: valuation allowance	-46,976,000	-35,397,000
Deferred Tax Assets, Net of Valuation Allowance	$0	$0

Income_Taxes_Effective_Income_

Income Taxes - Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax [Line Items]	'	'
Statutory Federal tax rate	-34.00%	-34.00%
Statutory state and local income taxes (net of Federal)	-11.00%	-7.00%
Effect of valuation allowance	45.00%	41.00%
Effective tax rate	0.00%	0.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]	'	'
Deferred Tax Assets, Net of Valuation Allowance, Current	$11,579,000	$9,132,000
Statutory Federal tax rate	34.00%	34.00%
Effective Income Tax Rate Reconciliation, Tax Settlements, State and Local	11.00%	'
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	67,000,000	'
Deferred Tax Assets, Tax Credit Carryforwards, Research	2,149,000	'
Deferred Tax Assets, Operating Loss Carryforwards, Federal	$73,000,000	'
Minimum [Member]	'	'
Income Taxes [Line Items]	'	'
Operating Loss Carryforwards Expiration Period	'2027	'
Maximum [Member]	'	'
Income Taxes [Line Items]	'	'
Operating Loss Carryforwards Expiration Period	'2031	'

Commitments_Additional_Informa

Commitments - Additional Information (Details) (USD $)	12 Months Ended	3 Months Ended			12 Months Ended
	Dec. 31, 2013	Sep. 30, 2011	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	Chief Executive Officer [Member]	Chief Executive Officer [Member]	Chief Executive Officer [Member]	Chief Executive Officer [Member]	Chief Financial Officer [Member]	Chief Financial Officer [Member]	Chief Financial Officer [Member]
		First Threshold [Member]	First Threshold [Member]	Second Threshold [Member]		First Threshold [Member]	Second Threshold [Member]
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'	'	'	'
Annual base Salary	$375,000	'	'	'	$250,000	'	'
Guaranteed bonus	75,000	'	'	'	'	'	'
Annual performance-based bonus, percentage	50.00%	'	'	'	'	'	'
Bonus to be paid when the threshold met	'	'	250,000	500,000	'	250,000	500,000
Bonus paid because of the first threshold met	'	$250,000	'	'	'	$250,000	'

Stockholders_Transactions_Assu

Stockholders' Transactions - Assumptions for Fair Value of Warrants Granted (Details)	12 Months Ended
	Dec. 31, 2013
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'
Risk-free interest rate	3.89%
Expected volatility	128.18%
Expected life of warrants	'5 years
Expected dividend yield	0.00%

Stockholders_Transactions_Opti

Stockholders' Transactions - Option Activity and Related Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Shares	'	'
Outstanding at beginning of period	1,878,475	2,046,455
Granted	530,000	425,740
Exercised	0	-168,240
Forfeited	-69,984	-425,480
Outstanding at end of year	2,338,491	1,878,475
Options exercisable at end of period	2,322,518	1,618,820
Vested or expected to vest at December 31	2,338,491	1,878,475
Shares available on December 31 for options that may be granted	1,390,485	1,920,485
Weighted Average Exercise Price	'	'
Outstanding at beginning of period	$6.72	$6.40
Granted	$2.88	$7.64
Exercised	$0	$6.11
Forfeited	$7.60	$6.64
Outstanding at end of year	$5.87	$6.72
Options exercisable at end of period	$6.31	$6.51
Aggregate Intrinsic Value	'	'
Outstanding at end of year	$0	$0
Options exercisable at end of period	$0	$0

Stockholders_Transactions_Assu1

Stockholders' Transactions - Assumptions for Fair Value of Options Granted (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'	'
Risk-free interest rate, minimum	1.23%	1.11%
Risk-free interest rate, maximum	2.34%	1.32%
Expected life of options	'7 years	'7 years
Expected dividend yield	0.00%	0.00%
Maximum [Member]	'	'
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'	'
Expected volatility	77.34%	78.23%
Minimum [Member]	'	'
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]	'	'
Expected volatility	59.32%	76.31%

Stockholders_Transactions_Esti

Stockholders' Transactions - Estimated Future Stock-Based Compensation Expense Relating to Unvested Stock Options (Details) (USD $)	Dec. 31, 2013
Stockholders Equity Note [Line Items]	'
2014	$682,701
2015	275,820
2016	196,419
2017	20,239
Total estimated future stock-based compensation expense - stock options	$1,175,179

Stockholders_Transactions_Warr

Stockholders' Transactions - Warrant Activity and Related Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2007
Shares	'	'	'
Warrant, Outstanding at beginning of period	874,651	956,443	'
Warrant, Granted	0	0	'
Warrant, Exercised	0	81,792	12,903
Warrant, Expired	13,605	0	'
Warrant, Outstanding at end of year	861,046	874,651	'
Warrants exercisable at end of period	861,046	874,651	'
Weighted Average Exercise Price	'	'	'
Warrant, Outstanding at beginning of period	$7.67	$7.61	'
Warrant, Granted	$0	$0	'
Warrant, Exercised	$0	$7	'
Warrant, Expired	$1.24	$0	'
Warrant, Outstanding at end of year	$7.77	$7.67	'
Warrants exercisable at end of period	$7.77	$7.67	'

Stockholders_Transactions_Summ

Stockholders' Transactions - Summary Of Restricted Stock Units (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Line Items]	'
Restricted stock units as of January 1, 2013	0
Restricted stock units, Granted	500,000
Restricted stock units, vested and issuable	-125,000
Restricted stock units as of December 31, 2013	375,000
Restricted stock units, Weighted Average Grant Date Fair Value Per Share as of January 1, 2013	$0
Restricted stock units, Weighted Average Grant Date Fair Value, Granted	$2.27
Restricted stock units, Weighted Average Grant Date Fair Value, vested and issuable	$2.95
Restricted stock units, Weighted Average Grant Date Fair Value Per Share as of December 31, 2013	$2.04

Stockholders_Transactions_Addi

Stockholders' Transactions - Additional Information (Details) (USD $)

1 Months Ended

2 Months Ended

4 Months Ended

12 Months Ended

99 Months Ended

1 Months Ended

2 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Sep. 30, 2013

Feb. 28, 2013

Dec. 22, 2010

Dec. 31, 2009

Jul. 30, 2008

Jun. 30, 2012

Sep. 30, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2013

Feb. 28, 2013

Feb. 28, 2013

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2008

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 30, 2010

Dec. 31, 2009

Apr. 30, 2007

Dec. 31, 2010

Dec. 22, 2010

Aug. 31, 2007

Aug. 02, 2007

Jun. 30, 2007

11-May-10

Dec. 31, 2009

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2010

31-May-11

Aug. 31, 2010

Jul. 19, 2011

Aug. 31, 2007

Apr. 30, 2007

Dec. 31, 2009

Dec. 31, 2009

Dec. 31, 2010

Jan. 07, 2011

Dec. 31, 2007

Dec. 31, 2012

Dec. 31, 2007

Dec. 31, 2013

Feb. 12, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Feb. 12, 2012

Nov. 30, 2010

Nov. 30, 2010

Nov. 30, 2010

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2007

Aug. 05, 2013

Dec. 31, 2013

Aug. 05, 2013

Series A Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Exercise of warrants [Member]

S L Pharma [Member]

S L Pharma [Member]

S L Pharma [Member]

S L Pharma [Member]

S L Pharma [Member]

S L Pharma [Member]

S L Pharma [Member]

Employee Stock [Member]

Note 2007 [Member]

Note 2007 [Member]

Note 2007 [Member]

Notes 2010 [Member]

Notes 2010 [Member]

Notes 2010 [Member]

Notes 2010 [Member]

Underwritten Public Offering [Member]

Founders [Member]

Founders [Member]

Vendor [Member]

Vendor [Member]

Pbs and Capretti Grandi Llc [Member]

Underwriters [Member]

Consultants [Member]

Eight Employees [Member]

Eight Employees [Member]

Five New Employees [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

At-The-Market Common Equity Sales Program [Member]

Equity Incentive Plan 2010 [Member]

Equity Incentive Plan 2010 [Member]

Equity Incentive Plan 2010 [Member]

Equity Incentive Plan 2010 [Member]

Equity Incentive Plan 2010 [Member]

Equity Incentive Plan 2010 [Member]

Equity Incentive Plan 2010 [Member]

Equity Incentive Plan 2010 [Member]

Equity Incentive Plan 2010 [Member]

Stock Incentive Plan 2007 [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Maximum [Member]

Non Employee Directors [Member]

Chief Executive Officer [Member]

Chief Financial Officer [Member]

One Director [Member]

One Director [Member]

Seven Employees [Member]

Seven Consultants [Member]

Seven Consultants [Member]

Three Director [Member]

Four Employees [Member]

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Existing Shelf Registration Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000,000

'

'

'

'

'

'

$20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

220,000

6,670,000

1,129,545

2.46

'

18,977

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

368,012

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds raised from common stock issued in a public offering

'

'

'

'

'

4,166,000

'

'

'

'

'

'

'

'

'

'

3,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant, Exercised

'

'

'

'

'

'

'

0

81,792

'

'

'

12,903

'

'

'

'

'

'

'

'

'

'

'

'

50,034

'

'

'

'

'

'

'

'

'

'

'

'

285,417

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares approved Equity Incentive Plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,467,200

3,967,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercised Cashless Feature

'

'

'

'

'

'

'

'

47,550

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

228,000

228

500,000

'

'

'

'

'

'

'

'

160,000

573,599

305,920

35,000

'

'

162,740

'

30,000

'

'

'

'

Stock options granted, exercise price, lower limit

'

'

'

'

'

'

'

$2.47

$3.60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options granted, exercise price, Upper limit

'

'

'

'

'

'

'

$3.31

$10.62

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, Exercised

'

'

'

'

'

'

'

0

168,240

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,016

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option, weighted average remaining contractual life

'

'

'

'

'

'

'

'7 years 3 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

695,636

846,508

1,017,311

2,324,585

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised (in shares)

'

'

'

'

6,151

'

3,796

'

11,620

'

'

'

'

'

'

'

'

'

50,034

'

'

'

'

'

'

'

13,605

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

'

'

2,900,000

'

29,861

354,700

18,977

20,733,895

12,934,350

'

'

'

'

20,733,895

'

'

'

'

'

'

'

'

'

'

'

'

'

2,016

'

'

64,933

18,401

18,401

9,677

'

'

'

'

'

'

'

5,175,000

'

'

403

403

'

435,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Value, Issued

'

'

'

'

'

'

'

20,734

12,934

'

'

'

'

20,734

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

389,597

'

'

'

120

'

'

'

'

'

'

'

'

'

4,564

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock closing price

'

'

'

'

'

$11.75

$60.39

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Warrant Coverage

'

'

'

'

20.00%

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Private Placement Financing Per Unit

'

'

'

'

60.39

'

60.39

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment Warrants, Exercise Price

'

'

'

'

$66.46

'

$66.46

'

'

$5.77

$12.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.24

'

'

'

'

'

'

'

'

'

'

'

$6.60

'

'

'

'

'

'

$12.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Warrants

'

'

'

'

'

'

929,457

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Of Warrants Outstanding

'

'

'

'

340,860

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development

'

'

'

'

'

'

'

15,029,078

19,514,163

'

'

'

'

74,072,484

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

$4.20

'

'

'

'

'

'

$4.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage On Public Offering Price

'

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Public Offering Price Per Share

'

'

'

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,642,802

'

1,421,834

'

'

'

'

'

'

'

'

269,449

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Proceeds from initial public offering and other offerings

'

'

15,184,344

'

'

'

'

24,374,614

4,166,494

'

'

'

'

93,714,274

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

47,568,047

'

'

'

'

'

2,420,776

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Market Fair Value Of Common Stock Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Forfeited In Period

'

'

'

'

'

'

'

'

'

'

'

1,613

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment Options, Exercise Price

'

'

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6

'

$6

'

'

'

'

'

'

'

'

'

'

'

$7.69

'

'

'

'

'

'

$15.77

'

'

$6

'

$6

'

'

'

'

'

'

'

'

'

'

'

'

Options exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,714

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,016

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock- Based Research And Development Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

161,552

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

552,440

'

384,240

'

'

'

'

500,000

Percentage Of Option Granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.50%

4.00%

'

'

'

'

'

'

'

'

'

'

Warrants Exercise By Cashless Feature

'

'

'

'

'

'

'

'

35,958

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Employee Stock Purchase Plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

483,871

'

'

'

Convertible Preferred Stock Conversion Common Stock Shares Issuable

'

2,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ProceedsFromIssuanceOrSaleOfEquity

'

20,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Sales Incremental Value

20,521,567

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity Securities Value Available Under Shelf Registration Statement

'

'

'

'

'

'

'

75,000,000

'

'

'

'

'

75,000,000

'

'

'

16,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Restricted Stock Units Vested Descriptions

'

'

'

'

'

'

'

'The Company valued the restricted stock grant, 75% of which vests in three equal installments when the 20-day trading volume weighted average price of the Companys common stock is at least $4.15, $5.15 and $6.15, using the Monte Carlo simulation model.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'25% vested immediately at the grant date. The remaining 75% of the units will vest in equal 25% tranches if the 20 trading day volume-weighted average price of our common stock as reported on the NASDAQ Capital Market is at least $4.15, $5.15 and $6.15, respectively

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

77.34%

78.23%

'

59.32%

76.31%

'

'

'

'

'

'

'

'

'

'

'

'

'

56.10%

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.93%

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total

'

'

'

'

'

'

'

$1,135,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Stock Expensed Percentage

'

'

'

'

'

'

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

License_Agreements_Additional_

License Agreements - Additional Information (Details) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

99 Months Ended

0 Months Ended

1 Months Ended

53 Months Ended

Nov. 08, 2013

Nov. 14, 2011

Mar. 31, 2007

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 30, 2012

Jun. 06, 2011

Dec. 22, 2010

Sep. 30, 2008

Jul. 30, 2008

Nov. 08, 2013

Nov. 08, 2013

Nov. 08, 2013

Aug. 31, 2007

Dec. 22, 2010

Dec. 31, 2009

Aug. 02, 2007

Jun. 06, 2011

Jun. 06, 2011

Aug. 31, 2007

Aug. 31, 2007

Jun. 06, 2011

Dec. 31, 2011

Aug. 31, 2007

Jun. 06, 2011

CHINA

India and Brazil [Member]

All Other Countries [Member]

S L Pharma [Member]

S L Pharma [Member]

S L Pharma [Member]

S L Pharma [Member]

S.L.A. Pharma [Member]

S.L.A. Pharma [Member]

S.L.A. Pharma [Member]

S.L.A. Pharma [Member]

S.L.A. Pharma [Member]

S.L.A. Pharma [Member]

S.L.A. Pharma [Member]

S.L.A. Pharma [Member]

License Agreement [Member]

License Agreement [Member]

License Agreement [Member]

Diltiazem Project [Member]

Diltiazem Project [Member]

Diltiazem Project [Member]

Phenylephrine Project [Member]

Phenylephrine Project [Member]

Eliminated [Member]

Maximum [Member]

Maximum [Member]

License Agreement [Member]

License Agreement [Member]

License Agreement [Member]

Maximum [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

'

'

'

20,733,895

12,934,350

20,733,895

354,700

'

2,900,000

18,977

29,861

'

'

'

18,401

64,933

2,016

18,401

'

'

'

'

'

'

'

'

Market Fair Value Of Common Stock Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$500,000

'

$500,000

'

'

'

'

'

'

'

'

Reimbursement Of Clinical Development Costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

Potential milestone payment

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

250,000

'

'

'

800,000

1,000,000

20,000,000

'

'

'

'

'

Payment to acquire license

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,087,876

'

'

'

'

'

'

'

'

'

'

'

License agreement, monthly payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

41,500

'

'

41,500

'

Development costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

Payment made for services not yet provided

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

Supplemental disclosure - cash paid for interest

'

'

'

0

0

685,397

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,200,000

'

'

Additional Payments To Acquire Intangible Assets

'

12,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percent Of Share Issued On License Agreements

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment For Non refundable License Fee

$300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Milestones Paid

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

Private_Placements_Fair_Value_

Private Placements - Fair Value of the Placement Warrants (Details)	12 Months Ended
	Dec. 31, 2013
Fair Value Of The Placement Warrants [Line Items]	'
Risk-free interest rate	3.89%
Expected dividend yield	0.00%
Senior Convertible Notes 2007 [Member]	'
Fair Value Of The Placement Warrants [Line Items]	'
Expected Term	'7 years
Expected dividend yield	0.00%
Senior Convertible Notes 2007 [Member] | Maximum [Member]	'
Fair Value Of The Placement Warrants [Line Items]	'
Risk-free interest rate	3.84%
Expected Volatility Rate	123.73%
Senior Convertible Notes 2007 [Member] | Minimum [Member]	'
Fair Value Of The Placement Warrants [Line Items]	'
Risk-free interest rate	3.01%
Expected Volatility Rate	63.69%
Senior Convertible Notes 2010 [Member]	'
Fair Value Of The Placement Warrants [Line Items]	'
Risk-free interest rate	2.02%
Expected Volatility Rate	124.00%
Expected Term	'5 years
Expected dividend yield	0.00%

Private_Placements_Additional_

Private Placements - Additional Information (Details) (USD $)

1 Months Ended

4 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Jul. 30, 2008

Sep. 30, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2007

Feb. 26, 2010

Dec. 31, 2007

Dec. 31, 2007

Dec. 31, 2007

Dec. 31, 2007

Dec. 31, 2010

31-May-10

Feb. 26, 2010

Dec. 31, 2009

Paramount [Member]

Third Party Agents [Member]

Private Placement [Member]

Note 2007 [Member]

Notes 2010 [Member]

Notes 2010 [Member]

Notes 2010 [Member]

Placement Warrants [Member]

Bridge Notes [Member]

Private Placements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Rate

'

'

'

'

'

'

'

70.00%

'

'

'

8.00%

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

$5,617,433

'

'

$5,305,000

'

$3,425,000

$3,425,000

$2,192,433

'

Debt Instrument, Interest Rate, Effective Percentage

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

Debt Conversion, Description

'

'

'

'

'

'Each 2010 Noteholder holds a warrant to purchase that number of shares of the Company’s common stock equal to 50% of the principal amount of the 2010 Notes purchased by it divided by the IPO Price at a per share exercise price equal to 110% of the IPO Price, subject to adjustment

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature

'

'

'

'

'

'

'

'

'

'

'

'

2,957,187

'

'

'

'

Interest Expense, Debt

'

'

'

'

'

3,779,269

'

'

'

'

'

'

6,899,770

'

'

'

'

Debt Instrument Beneficial Convertible Feature and Interrest

'

'

'

'

'

5,398,956

'

'

'

'

'

'

9,856,957

'

'

'

'

Payments for Commissions

'

'

'

'

'

'

'

'

'

243,600

19,250

'

'

'

'

'

'

Warrant, Exercised

'

'

0

81,792

'

'

'

12,903

'

'

'

'

'

285,417

'

'

42,782

Percentage Of Warrant On Principal Amount Of Debt Instrument

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

Investment Warrants, Exercise Price

$66.46

$66.46

'

'

$5.77

'

$12.40

'

'

'

'

'

'

$6.60

'

'

'

Deferred Tax Liabilities, Deferred Expense, Deferred Financing Costs

'

'

'

'

'

'

341,000

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Carrying Amount of Equity Component

'

'

'

'

'

$1,429,590

'

'

$1,421,834

'

'

'

'

'

$1,619,687

'

'

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Details) (USD $)

12 Months Ended

1 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2008

Jun. 30, 2012

Sep. 30, 2008

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2014

Jan. 31, 2014

Jan. 31, 2014

Jan. 31, 2014

Jan. 31, 2014

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Chief Executive Officer [Member]

Chief Financial Officer [Member]

Common Stock [Member]

Series A Preferred Stock [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Officers Compensation

'

'

'

'

'

'

'

'

$475,000

$300,000

'

'

Percentage Of Discretionary Bonus On Base salary

'

'

'

'

'

'

'

50.00%

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

220,000

'

'

'

'

'

462,364

'

Stock Issued During Period, Value, New Issues

$19,204,614

$929,457

'

'

'

'

'

'

'

'

$1,763,000

'

Sale Of Stock, Price Per Share

'

'

$11.75

$60.39

'

'

'

'

'

'

$3.81

'

Preferred Stock, Shares Outstanding

'

'

'

'

'

220,000

0

'

'

'

'

220,000

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

2,200,000

'

'

'

'